Application of apatinib after multifaceted therapies for metastatic breast cancer

BACKGROUND: Apatinib is a small molecule tyrosine kinase inhibitor (TKI) that is taken orally and has high specificity for vascular endothelial growth factor receptor 2 (VEGFR-2). This study explored the efficacy and toxicity of apatinib in patients with metastatic breast cancer (MBC) who failed to...

Descripción completa

Detalles Bibliográficos
Autores principales: Wang, Jue, Chen, Yangyang, Chen, Renwang, Wu, Lu, Cheng, Jing
Formato: Online Artículo Texto
Lenguaje:English
Publicado: AME Publishing Company 2020
Materias:
Original Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8797807/
https://www.ncbi.nlm.nih.gov/pubmed/35117814
http://dx.doi.org/10.21037/tcr-19-2588

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8797807/
https://www.ncbi.nlm.nih.gov/pubmed/35117814
http://dx.doi.org/10.21037/tcr-19-2588

Ejemplares similares